LEXINGTON, Mass., Nov. 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ:
CRIS), a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer, today
announced that Curis management will participate in virtual
fireside chats and panels at the following upcoming conferences in
November and December:
- 30th Annual Credit Suisse Healthcare Conference on
Monday, November 8, 2021 at
1:00 p.m. ET
-
- Jim Dentzer, President and CEO,
will participate in the virtual fireside chat.
- 12th Annual Jefferies Global Healthcare Conference,
starting on Thursday, November 18,
2021 at 3:00 a.m. ET
(8:00 a.m. GMT).
-
- Jim Dentzer, President and CEO,
will participate in the virtual fireside chat that will be
available for on-demand viewing during the conference.
- B. Riley Fall Best Ideas in Oncology Panel Series on
Wednesday, December 1, 2021 at
11:00 a.m. ET
-
- Robert Martell, Head of Research
and Development, will participate on the oncology panel series
titled "Emerging Targeted Therapies in Acute Myeloid Leukemia"
Live webcasts of the Credit Suisse and B. Riley presentations
will be available under "Events & Presentations" in the
Investors section of the Company's website at www.curis.com.
Archived replays for all the events will be available on the Curis
website for approximately 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently
undergoing testing in a Phase 1/2 trial in patients with
non-Hodgkin's lymphoma both as a monotherapy and in combination
with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a
Phase 1/2 trial in patients with acute myeloid leukemia and
myelodysplastic syndromes, for which it has received Orphan Drug
Designation from the U.S. Food and Drug Administration. In
addition, Curis is engaged in a collaboration with ImmuNext for
development of CI-8993, a monoclonal anti-VISTA antibody,
which is currently undergoing testing in a Phase 1 trial in
patients with solid tumors. Curis is also party to a collaboration
with Genentech, a member of the Roche Group, under which Genentech
and Roche are commercializing Erivedge® for the
treatment of advanced basal cell carcinoma. For more information,
visit Curis's website at www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-investor-conferences-301413970.html
SOURCE Curis, Inc.